TNC trades 54.3% below Wall Street's consensus target of $140.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TNC achieves its forward estimates and maintains a stable P/E multiple of 17.7x. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Tennant Company (TNC) has a Wall Street consensus price target of $140.00, based on estimates from 8 covering analysts. With the stock currently trading at $90.75, this represents a potential upside of +54.3%. The company has a market capitalization of $1.63B.
Analyst price targets range from a low of $140.00 to a high of $140.00, representing a 0% spread in expectations. The median target of $140.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, TNC trades at a trailing P/E of 38.5x and forward P/E of 17.7x. The forward PEG ratio of 3.25 reflects a premium valuation. Analysts expect EPS to grow +194.8% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $126.10, with bear and bull scenarios of $79.44 and $166.15 respectively. Model confidence stands at 40/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NDSNNordson Corporation | $16.5B | $295.92 | $323.80 | +9.4% | Buy | 25.5x | 21 |
KAIKadant Inc. | $3.6B | $304.49 | $303.00 | -0.5% | Hold | 33.1x | 6 |
MIDDThe Middleby Corporation | $7.8B | $172.26 | $200.00 | +16.1% | Buy | 18.0x | 20 |
TTNPTitan Pharmaceuticals, Inc. | $4M | $3.08 | — | — | — | — | — |
ASTEAstec Industries, Inc. | $1.3B | $56.12 | $36.00 | -35.9% | Buy | 15.6x | 12 |
HLIOHelios Technologies, Inc. | $3.0B | $90.49 | $82.67 | -8.6% | Buy | 35.8x | 13 |
ECLEcolab Inc. | $76.0B | $269.12 | $326.91 | +21.5% | Buy | 32.4x | 37 |
CLXThe Clorox Company | $11.6B | $95.80 | $105.50 | +10.1% | Hold | 17.3x | 28 |
SHWThe Sherwin-Williams Company | $79.1B | $320.79 | $374.56 | +16.8% | Buy | 27.4x | 38 |
MMM3M Company | $83.8B | $160.60 | $166.75 | +3.8% | Hold | 18.5x | 33 |
Quick answers to the most common questions about buying TNC stock.
The consensus Wall Street price target for TNC is $140, representing 54.3% upside from the current price of $90.75. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
TNC has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $140 implies 54.3% upside from current levels.
With a forward P/E of 17.736x, TNC trades at a relatively low valuation. The consensus target of $140 implies 54.3% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $140 for TNC, while the most conservative target is $140. The consensus of $140 represents the median expectation. Our quantitative valuation model projects a bull case target of $166 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
TNC is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TNC stock forecast based on 8 Wall Street analysts shows a consensus price target of $140, with estimates ranging from $140 (bear case) to $140 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $126, with bear/bull scenarios of $79/$166.
Our quantitative valuation model calculates TNC's fair value at $126 (base case), with a bear case of $79 and bull case of $166. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 40/100.
TNC trades at a forward P/E ratio of 17.7x based on next-twelve-months earnings estimates compared to a trailing P/E of 38.5x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on TNC, with a "Buy" consensus rating and $140 price target (54.3% upside). 6 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TNC analyst price targets range from $140 to $140, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $140 consensus represents the middle ground. Our model's $79-$166 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.